TR201802305T4 - Kinolon türevleri. - Google Patents

Kinolon türevleri. Download PDF

Info

Publication number
TR201802305T4
TR201802305T4 TR2018/02305T TR201802305T TR201802305T4 TR 201802305 T4 TR201802305 T4 TR 201802305T4 TR 2018/02305 T TR2018/02305 T TR 2018/02305T TR 201802305 T TR201802305 T TR 201802305T TR 201802305 T4 TR201802305 T4 TR 201802305T4
Authority
TR
Turkey
Prior art keywords
acetic acid
carboxamide
preparation
dihydroquinoline
hydroxy
Prior art date
Application number
TR2018/02305T
Other languages
English (en)
Turkish (tr)
Inventor
C Desai Ranjit
Pandya Vrajesh
R Patel Pankaj
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201802305(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of TR201802305T4 publication Critical patent/TR201802305T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TR2018/02305T 2012-12-24 2013-12-23 Kinolon türevleri. TR201802305T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3600MU2012 2012-12-24

Publications (1)

Publication Number Publication Date
TR201802305T4 true TR201802305T4 (tr) 2018-03-21

Family

ID=54148255

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/02305T TR201802305T4 (tr) 2012-12-24 2013-12-23 Kinolon türevleri.

Country Status (26)

Country Link
US (1) US9394300B2 (2)
EP (1) EP2935221B1 (2)
JP (1) JP6026013B2 (2)
KR (1) KR101733901B1 (2)
CN (1) CN104903295B (2)
AP (1) AP2015008502A0 (2)
AR (1) AR094300A1 (2)
AU (1) AU2013368843B2 (2)
BR (1) BR112015014222B1 (2)
CA (1) CA2894636C (2)
CL (1) CL2015001802A1 (2)
EA (1) EA028402B1 (2)
ES (1) ES2660288T3 (2)
IL (1) IL239109B (2)
JO (1) JO3781B1 (2)
MA (1) MA38138A1 (2)
MX (1) MX373392B (2)
MY (1) MY175854A (2)
NZ (1) NZ708605A (2)
PH (1) PH12015501452B1 (2)
SG (1) SG11201504458XA (2)
TR (1) TR201802305T4 (2)
TW (1) TWI598339B (2)
UA (1) UA117122C2 (2)
WO (1) WO2014102818A1 (2)
ZA (1) ZA201503814B (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6506390B2 (ja) * 2014-09-02 2019-04-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． キノリノン系化合物及びその薬物への使用
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
CA3062972C (en) * 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
TW202200547A (zh) * 2020-03-13 2022-01-01 印度商卡地拉保健有限公司 喹啉酮化合物的新穎鹽類
WO2021186356A1 (en) * 2020-03-17 2021-09-23 Cadila Healthcare Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2021240454A1 (en) * 2020-05-29 2021-12-02 Cadila Healthcare Limited Treatment for psoriasis and skin inflammatory diseases
WO2021245533A1 (en) * 2020-06-01 2021-12-09 Cadila Healthcare Limited Treatment for the inflammatory bowel disease
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN116997331A (zh) * 2021-03-19 2023-11-03 兹杜斯生命科学有限公司 固体形式的喹诺酮化合物及其制备方法
WO2022195532A1 (en) 2021-03-19 2022-09-22 Zydus Lifesciences Ltd. Treatment for sickle cell anaemia
WO2022238745A1 (en) * 2021-05-14 2022-11-17 Zydus Lifesciences Limited Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN113549011B (zh) * 2021-08-10 2023-05-09 广东东阳光药业有限公司 德度司他的共晶或盐及其制备方法和用途
US20240408022A1 (en) * 2021-09-20 2024-12-12 Zydus Lifesciences Limited Desidustat particles and compositions thereof
US20250387385A1 (en) * 2022-06-24 2025-12-25 Zydus Lifesciences Limited Treatment for glomerular diseases
EP4565233A1 (en) * 2022-08-01 2025-06-11 Zydus Lifesciences Limited Treatment for aplastic anemia (aa)
AU2024366956A1 (en) 2023-10-24 2026-04-09 Kind Pharmaceutical Long-acting oral pharmaceutical comprising hypoxia-inducible factor prolyl hydroxylase inhibitor and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2006094292A2 (en) * 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
JP5202327B2 (ja) * 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
CN103497184A (zh) * 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2142509B1 (en) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
CA2683758A1 (en) * 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
US8097620B2 (en) * 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
ES2389063T3 (es) * 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
WO2008138060A1 (en) * 2007-05-16 2008-11-20 Cowper Norman T System and method for maximising solids concentration of slurry pumped through a pipeline
WO2009070644A1 (en) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011513222A (ja) * 2008-02-25 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション テトラヒドロチエノピリジン
CA2714111A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1h-pyrrolo fused pyridones
CN101951777A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢呋喃并吡啶酮
JP2011525924A (ja) * 2008-06-25 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
SI2455381T1 (sl) 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
AR077892A1 (es) * 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
WO2013043621A1 (en) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
JPWO2013115265A1 (ja) * 2012-01-31 2015-05-11 富山化学工業株式会社 抗ｈｉｖ活性を有する複素環化合物

Also Published As

Publication number Publication date
PH12015501452B1 (en) 2018-06-06
MX373392B (es) 2020-04-20
AR094300A1 (es) 2015-07-22
IL239109A0 (en) 2015-07-30
CN104903295B (zh) 2017-09-01
MX2015008233A (es) 2015-09-29
BR112015014222A2 (pt) 2017-07-11
AU2013368843A1 (en) 2015-06-18
KR101733901B1 (ko) 2017-05-08
AU2013368843B2 (en) 2016-02-25
ZA201503814B (en) 2016-05-25
CN104903295A (zh) 2015-09-09
JO3781B1 (ar) 2021-01-31
HK1211022A1 (en) 2016-05-13
EA201591195A1 (ru) 2015-10-30
US20150299193A1 (en) 2015-10-22
PH12015501452A1 (en) 2015-09-21
EP2935221B1 (en) 2018-02-07
WO2014102818A1 (en) 2014-07-03
TW201441196A (zh) 2014-11-01
KR20150085535A (ko) 2015-07-23
EP2935221A1 (en) 2015-10-28
IL239109B (en) 2019-07-31
BR112015014222B1 (pt) 2022-12-06
CL2015001802A1 (es) 2015-10-02
JP6026013B2 (ja) 2016-11-16
US9394300B2 (en) 2016-07-19
AP2015008502A0 (en) 2015-06-30
MY175854A (en) 2020-07-14
UA117122C2 (uk) 2018-06-25
MA38138A1 (fr) 2016-11-30
TWI598339B (zh) 2017-09-11
EA028402B1 (ru) 2017-11-30
NZ708605A (en) 2016-07-29
CA2894636A1 (en) 2014-07-03
CA2894636C (en) 2018-04-03
ES2660288T3 (es) 2018-03-21
SG11201504458XA (en) 2015-07-30
JP2016503052A (ja) 2016-02-01

Similar Documents

Publication Publication Date Title
TR201802305T4 (tr) Kinolon türevleri.
CN109071468B (zh) 一种杂环化合物及其制备方法和用途
CN108430998B (zh) 氮杂双环衍生物及其制备方法和用途
JP5269086B2 (ja) ヒト免疫不全ウイルスの複製阻害薬
KR20250133486A (ko) THRβ 수용체 효능제 화합물 및 그의 제조 방법 및 용도
KR20100108337A (ko) 사람 면역결핍 바이러스 복제의 억제제
EP4402126A1 (en) Ahr agonists
JP2020534275A (ja) 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬
CN115785064B (zh) 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
IE912147A1 (en) New acylbenzoxazolinones, process for preparing them and¹pharmaceutical compositions containing them
CN104395312B (zh) 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用
AU2023256071A1 (en) Gpcr regulator and use thereof
CN104016942B (zh) 噻唑啉酮类衍生物及其药物组合物与应用
JP7518533B2 (ja) 新規イノン化合物及びその用途
CA3235475A1 (en) Process
HK1211022B (en) Quinolone derivatives
CN118580215A (zh) 一种具有抗肿瘤活性的胡椒酸酯类化合物及其制备方法和应用
OA17332A (en) Novel quinolone derivatives.
WO2026012438A1 (en) Novel alpk1 inhibitors
HK40023798A (en) Isoxazole derivative, preparation method therefor, and use thereof
CN110357876A (zh) 氮杂双环辛烷类衍生物及其制备方法和用途
Li Studies toward the total synthesis of herbimycin A, B, C, and geldanamycin
JP2016508118A (ja) Ｋｃｎｑ２／３モジュレーターとしての置換アミノ−アリールカルボキサミド